<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245905</url>
  </required_header>
  <id_info>
    <org_study_id>CSIIT-B09</org_study_id>
    <nct_id>NCT03245905</nct_id>
  </id_info>
  <brief_title>Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL</brief_title>
  <official_title>Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide
      as a single-agent treatment in patients with relapsed or refractory B-cell Non-Hodgkin's
      Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate（ORR）</measure>
    <time_frame>every 6 weeks until 2 years after last patient's enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival（PFS）</measure>
    <time_frame>every 6 weeks until 2 years after last patient's enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>every 6 weeks until 2 years after last patient's enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>Chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide 30mg orally BIW (d1, 4, 8, 11, 15, 18). Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.</description>
    <arm_group_label>Chidamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed as B-cell Non-Hodgkin's Lymphoma (NHL) according to &quot;2008 WHO classification
             of tumors of haematopoietic and lymphoid tissues&quot;, including Diffuse Large B-Cell
             Lymphoma (DLBCL), Follicular Lymphoma (FL) grade 1-3, Marginal Zone Lymphoma (MALT),
             Lymphoplasmacytic Lymphoma (LPL), Small Lymphocytic Lymphoma (SLL), Mantle Cell
             Lymphoma (MCL), transformed indolent lymphoma (TL), and other subtypes that
             investigators consider to be appropriate to be enrolled;

          2. Patients achieved CR or PR in previous cytotoxic chemotherapy, and relapsed later than
             6 months after remission;

          3. Patients with DLBCL, FL grade3, MALT, LPL and SLL received at least two chemotherapy
             regimens, and Patients with FL grade1-2 received at least three chemotherapy regimens;

          4. At least one measurable lesion with a longest diameter &gt;1.5cm or a short axis &gt;1.0cm;

          5. Age18-75 years;

          6. ECOG performance status 0-2;

          7. Life expectancy no less than 3 months;

          8. Functions within 7 days prior to enrollment: Blood routine test: Hb ≥ 80g/L, absolute
             neutrophil count ≥1.5 × 109/L, platelet ≥60 × 109/L; Total bilirubin ≤ 1.5 times of
             normal maximum, ALT/AST≤ 2.5 times of normal maximum, for patients with liver
             metastasis ALT/AST≤ 5 times of normal maximum; serum creatinin≤1.5 times of normal
             maximum or CCr≥ 60ml/min;

          9. LVEF ≥ 50% by echocardiography;

         10. Contraception during and 4 weeks after the study for patients at child bearing age;

         11. Patients have signed the Informed Consent Form.

        Exclusion Criteria:

          1. Patients received Chidamide treatment within 6 months prior to enrollment;

          2. Patients with Burkitt Lymphoma, B-lymphoblastic lymphoma, central nervous system
             lymphoma and HIV-Associated Lymphoma;

          3. Patients with a &quot;currently active&quot; second malignancy;

          4. Patients not recovered from non-hematologic toxicities within 4 weeks prior to
             enrollment due to chemotherapy, radiation and immunotherapy;

          5. Patients receiving or received corticosteroids within 2 weeks prior to enrollment;

          6. Patients with cumulative life time dose of Doxorubicin &gt; 450mg/m2;

          7. Patients who have been treated with any investigational drug within 4 weeks prior to
             enrollment;

          8. Women during pregnancy or lactation;

          9. Patients with active infection, medical conditions, or mental disorders;

         10. Patients with active infection of HBV, HCV or HIV;

         11. Congestive heart failure (NYHA grade III/IV), myocardial infarction within 6 months,
             QTc elongation with clinical significance (≥480ms), hypertension BP≥150/100 mmHg and
             symptomatic coronary heart disease that require treatment;

         12. Patients with drug abuse, long term alcoholism that may impact the results of the
             trial;

         13. Non-appropriate patients for the trial according to the judgment of the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Oncology, Sun Yat-sen University Cancer Center,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huiqiang Huang</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

